Specialized Disclosure Report (sd)

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM SD

 

 

Specialized Disclosure Report

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware		001-15317		98-0152841
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
9001 Spectrum Center Blvd. San Diego, California 92123
(Address of Principal Executive Offices)

 

 

David Pendarvis

[phone]

(Name and telephone number, including area code, of the person to contact in connection with this report.)

 

 

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

 

☒	Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2019.

 

 

 

---

Section 1 – Conflict Minerals Disclosure

Item 1.01 and Item 1.02 Conflict Minerals Disclosure and Report, Exhibits

Conflict Minerals Disclosure

This Form SD of ResMed Inc. is filed in accordance with Exchange Act Rule 13p-1, and covers the reporting period from January 1, 2019 through December 31, 2019.

The description of our reasonable country of origin inquiry process, the results of our inquiry, and the determination we reached as a result of our reasonable country of origin inquiry process is included in our conflict minerals report attached as an exhibit to this Form SD. A copy of our conflict minerals report for the reporting period January 1, 2019 to December 31, 2019 is provided as Exhibit 1.01 and is available at www.resmed.com> For Investors > Corporate Governance > Corporate Governance Documents.

Section 2 – Exhibits

Item 2.01 Exhibits

The following exhibit is filed as part of this report.

Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2019 to December 31, 2019.

 

2

---

SIGNATURES

We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

 

Date: May 22, 2020				RESMED INC.
				(registrant)
				By:		/s/ David Pendarvis
				Name:		David Pendarvis
				Its:		Chief administrative officer, global general counsel and secretary

 

3